Integration of the problem of medical ecology on the level of the highly urbanized region

The urgency of the analyzed issue is due to the study of the basic issues of medical ecology: the dynamics of demographic indicators, the correlation of somatic and reproductive public health, depending on the influence of physical factors of the urban environment on public health on the basis of medical and geographic mapping. The article aims at the analysis of the environmentally determined disorder of the urbanized territory. The leading approach to the study of the issue of medical ecology is a medical and geographical mapping, which allows identifying the most affordable and common areas of multi-component medical and environmental maps. While analyzing the impact of various aspects of the environment on human health, the priority is given to risk factors that directly lead to the emergence of diseases. The contents of the article may be useful to justify the choice of the rational approach to public health as a redistribution mechanism to reallocate the space of ecological niches. © 2016 Rozenberg et al

THE ANALYSIS OF GROWTH OF NUMBER DIED AMONG THE POPULATION OF THE VOLGA RIVER BASIN IN THE SUMMER OF 2010

The estimation of essential growth of number of cases of death among the population of the Volga pool, as possible consequence of a record thermal wave of summer of 2010 is spent. The analysis of distribution of principal causes of death is given. It is presented regression model of the contribution of influence of meteorological factors on number died of illnesses of system of blood circulation

HUMAN ECOLOGY IN DISSERTATION STUDIES OF 2005-2012

There are discussed the defended PhD studies of 2005-2012 in some way related to the problems of human ecology. There was made a conclusion about the necessity to correct the concepts of "human ecology" in the specialty passport, consolidating the research area of ecology

Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study

This multicenter, double-blind, randomized study compared the efficacy, pharmacokinetics (PKs)/pharmacodynamics (PDs), safety and immunogenicity profile of RTXM83 vs. reference rituximab (R-rituximab), both with CHOP, as first-line treatment of diffuse large B-cell lymphoma (DLBCL). A total of 272 patients <65 years of age, with good prognosis (136 per arm) were randomized (1:1) to receive six cycles of either RTXM83 or R-rituximab. The primary efficacy endpoint was achieved (overall response rate of 83.6% for RTXM83 and 82.9% for R-rituximab) with a difference 0.7% between arms (95%CI: [-8.77% to 10.17%]) fulfilling the predefined non-inferiority margin (-13%). Similar number of patients reported at least one adverse event (AE) (131 per arm) or one serious AE (47 with RTXM83 and 45 with R-rituximab). Anti-drug antibody development was comparable between the arms. PK/PD secondary endpoint results support similarity between the compounds. RTXM83 exhibits non-inferior efficacy and similar safety/immunogenicity to R-rituximab, being an accessible alternative for the treatment of patients with previously untreated DLBCL